₹ 272000 / 3200 Shares Shares
Minimum Investment
₹80-85 per equity share
01 Dec 2025
03 Dec 2025
1600
₹ 272000
₹80-85
08 Dec 2025
33,08,800 shares(aggregating up to ₹28.12 crore)
₹10 Per Equity Share
3200 Shares
3200 Shares
Incorporated in January 2021, Invicta Diagnostic Limited offers radiology and pathology solutions. It provides pathology and radiology testing comprising imaging, radiology, pathology, and teleradiology services under the brand 'PC Diagnostics” through 7 diagnostic centres and a central laboratory across Mumbai in Maharashtra. Invicta Diagnostics Limited, trading as PC Diagnostics, is a Mumbai-based diagnostic services company specializing in integrated pathology and radiology solutions. The company follows a hub‑and‑spoke model across the Mumbai Metropolitan Region, featuring: A flagship hub offering full-spectrum pathology and advanced radiology (CT, MRI) at Thane West Three other centres - Bhayandar, Byculla, Marol - offering specialized diagnostic services Basic imaging, including X-ray and ultrasound, and sample collection were the focus of spokes at Lower Parel, Sewri, Mazgaon, and Kalwa. It offers approximately 60 routine and 487 specialized pathology tests and around 96 basic and 130 advanced radiology investigations. Invicta Diagnostics provides a comprehensive suite of diagnostic services that includes: Routine Tests: Includes CBC, lipid profiles, liver function tests (LFT), kidney function tests (KFT), and thyroid panels Specialized Tests: Molecular diagnostics, immunoassays, infectious disease markers including dengue, COVID-19, cancer markers, and genetic panels. Sample Collection Network: Invicta uses phlebotomists and collection partners to reach patients at home or through its spoke centres. The company has a network of 5 laboratory doctors, 20 radiologists, and 127 well-trained technical staff as of May 31st, 2025. The company has 105 permanent employees as of May 31, 2025.
2021
Dr. Ketan Jayantilal Jain
Invicta Diagnostic Limited IPO
| Apply as | Price Range | Apply Upto |
|---|---|---|
| Individual (min) | ₹80-85 | ₹2,72,000 |
| Individual(max) | ₹80-85 | ₹2,72,000 |
| SHNI(min) | ₹80-85 | ₹4,08,000 |
| SHNI(max) | ₹80-85 | ₹9,52,000 |
| BHNI(min) | ₹80-85 | ₹10,88,000 |
Apply for all eligible candidates, Invicta Diagnostic Limited IPO.
Yes, KSquare offers fund highlights, investment strategy, and expert opinions to help you evaluate each NFO thoroughly.
Yes, joint investments are allowed with a resident Indian, provided KYC and bank account norms are met.
The Asset Management Company (AMC) designs and manages the NFO, ensuring strategy alignment and regulatory compliance.
Tier I is the mandatory retirement account with tax benefits, while Tier II is voluntary with flexible withdrawals but no tax deductions.
Most mutual funds offer liquidity, allowing you to redeem units anytime, except for closed-ended and ELSS funds with lock-ins.
Yes, KSquare builds dedicated SIP plans focused on medical security so unexpected health expenses don’t affect regular finances.
The longer the duration, the better the returns. Ideally, stay invested for at least 5–10 years for best results.
Yes, NRIs can invest in NPS if they meet KYC norms. KSquare supports NRI onboarding for NPS accounts.
Ksquare Timeline Pvt. Ltd. is an AMFI Registered Mutual Fund Distributor having ARN No. 146262. Mutual Fund investments are subject to market risks. Please read all scheme related documents carefully before investing. This website is intended only for informational and self-help purposes and should not be considered as investment advice or return guarantee. Past performance is not indicative of future results. Terms & Conditions apply.